SGIOY Projected Dividend Yield
ADR/Shionogi & Co., Ltd. ( OTCBB : SGIOY )Shionogi is the parent company of a group engaged in the research and development, purchase, manufacture and sale of pharmaceuticals, diagnostic reagents and medical devices. Co.'s principal prescription drugs are "Tivicay" for HIV treatment, "Mulpleta" for thrombocytopenia treatment, " Sympronic" for opioid-induced constipation treatment, " "Xofluza," influenza drug, and "Fetroja (cefiderocol)" for multidrug-resistant Gram-negative bacterial infection treatment. Co. is also engaged in the OTC drug business. Its principal products include "Sedes First," "Sedes Hi G," "Pylon," "Rapiacta Bag" and "Rapiacta Vial." 18 YEAR PERFORMANCE RESULTS |
SGIOY Dividend History Detail SGIOY Dividend News SGIOY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2024 |
N/A |
N/A |
Sep 30, 2024 |
Dec 17, 2024 |
0.1414 |
2024 |
N/A |
N/A |
Mar 28, 2024 |
Jul 08, 2024 |
0.0591 |
2024 Total: |
0.2005 |
||||
2023 |
N/A |
N/A |
Sep 29, 2023 |
Dec 18, 2023 |
0.0566 |
2023 |
N/A |
N/A |
Mar 31, 2023 |
Jul 07, 2023 |
0.0584 |
2023 Total: |
0.1150 |
||||
2022 |
N/A |
N/A |
Sep 30, 2022 |
Dec 16, 2022 |
0.0488 |
2022 |
N/A |
N/A |
Mar 30, 2022 |
Jul 11, 2022 |
0.0493 |
2022 Total: |
0.0981 |
||||
2021 |
N/A |
N/A |
Sep 29, 2021 |
Dec 16, 2021 |
0.0539 |
2021 |
N/A |
N/A |
Mar 30, 2021 |
Jul 08, 2021 |
0.0550 |
2021 Total: |
0.1089 |
||||
2020 |
N/A |
N/A |
Sep 29, 2020 |
Dec 16, 2020 |
0.0563 |
2020 |
N/A |
N/A |
Mar 30, 2020 |
Jul 09, 2020 |
0.0551 |
2020 Total: |
0.1115 |
||||
2019 |
N/A |
N/A |
Sep 27, 2019 |
Dec 17, 2019 |
0.0508 |
2019 |
N/A |
N/A |
Mar 29, 2019 |
Jul 05, 2019 |
0.0512 |
2019 Total: |
0.1019 |